NRG Oncology opens new “ARCHER” clinical trial (NRG-GU015) testing a shorter treatment duration of radiation therapy for muscle invasive bladder cancer
NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adult cancers, recently opened a new clinical trial “ARCHER” (NRG-GU015) to study a shorter duration of radiation therapy for patients with muscle invasive bladder cancer.
“A quarter of all bladder cancers in the United States are muscle-invasive bladder cancers. Currently, the standard of care treatment for this disease consists of either (1) bladder preservation with transurethral ...